Anticoagulant-induced changes on antibiotic concentrations in the serum and bones

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 3, 2008, Pages 173-179

  Kotsiou, A ^a   Diamanti, E ^a   Potamianou, A ^a   Parara, H ^a   Vovou, J ^a   Perisanidis, C ^b   Tesseromatis, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anticoagulants; Bones; Quinolones

Indexed keywords

ACENOCOUMAROL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CEFAPIRIN; CIPROFLOXACIN; PEFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BONE LEVEL; FEMUR; MALE; MANDIBLE; NONHUMAN; PROTHROMBIN TIME; RAT; WISTAR RAT;

EID: 56249114132     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191115     Document Type: Article

References (50)

1. Jankel C.A., Speedie S.M. (1990): Detecting drug inter-actions: a review of the literature. DICP, 24, 982-989.
2. Prince B.S., Goetz C.M., Rihn T.L., Olsky M. (1992): Drug-related emergency department visits and hospital admissions. Am. J. Hosp. Pharm., 49, 1696-1700.
3. Jankel C.A., Fitterman L.K. (1993): Epidemiology of drug-drug interactions as cause of hospital admission. Drug Safety, 9, 51-59.
4. Koch K.M. (1982): Drug utilization in office practice by age and sex of patient: national ambulatory medical care survey 1980. Advance Data, 81, 1-2.
5. Leape L.L, Brenan T.A, Laird. (1991): The nature of adverse events in hospitalised patients: results of the Harvard Medical Practise Study II. N. Engl. J. Med., 324, 377-384.
6. Koch-Wesser J., Sellers M.S. (1971): Druginteractions with coumarin anticoagulants. N. Engl. J. Med., 285, 487-498.
7. Koch-Wesser J., Grenblatt D.J. (1977): Drug interactions in clinical prespective. Eur. J. Clin. Pharmacol., 11, 405-412.
8. Jick H. (1984): Adverse drug reactions: the magnitude of the problem. J. Allergy Clin. Immunol., 74, 555-557.
9. Tawara S., Matsumoto S., Matsumoto Y., Kamimura T., Goto S. (1992): Structure-binding relationship and binding sites of cephalosporins in human serum albumin. J. Antibiot., 45, 1346-1357.
10. Jones C.B., Fugate S.E., Pea F., Furlanut M. (2001): Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin. Pharmacokinet., 40, 833-868.
11. Alvan G. (1992): Genetic polymorphisms in drug metabolism. J. Internal. Med., 231, 571-573.
12. Harder S., Thunman P. (1996): Clinically important drug interaction with coagulants. An update. Clin. Pharmacokinet., 30, 416-444
13. Hansten P.D., Horn J.R..(1993): Drug interactions and updates 8th ed., Appl.Ther., Vancouver
14. Nelsestuen G.L., Zytkovicz T.H., Howard J.B. (1974): The mode of action of vitamin K: identification of
    -carboxyglutamic acid as a component of prothrombin. J. Biol. Chem., 249, 6347-6350.
15. Preyer S., Luckhaupt H. (1987): Antibiotics and blood coagulation-current references for the ENT physician. Laryngol. Rhinol. Otol. (Stuttg), 66, 107-109.
16. Bang N.U., Tessler S.S., Heidenreich R.O., Marks C.A., Mattler L.E. (1982): Effects of moxalactam on blood coagulation and platelet function. Rev. Infect. Dis., 4 Suppl, S546-554.
17. Mathews S., Cole J., Ryono R.A. (2006): Anticoagulation-related outcomes in patients receiving warfarin after starting levofloxacin or gatifloxacin. Pharmacotherapy, 26, 1446-1452.
18. Jones C.B., Fugate S.E. (2002): Levofloxacin and warfarin interaction. Ann. Pharmacother. 36, 1554-1557.
19. Heddle J.G., Barnard F.M., Wentzell L.M., Maxwell A. (2000): The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action. Nucleosides Nucleotides Nucleic Acids, 19, 1249-1264.
20. Lafitte D., Lamour V., Tsvetkov P.O., Makarov A.A., Klich M., Deprez P., Moras D., Briand C., Gilli R. (2002): DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5′-methyl group of the noviose. Biochemistry, 41, 7217-7223.
21. Ouahouo B.M., Azebaze A.G., Meyer M., Bodo B., Fomum Z.T., Nkengfack A.E. (2004): Cytotoxic and antimicrobial coumarins from Mammea africana. Ann. Trop. Med. Parasitol., 98, 733-739.
22. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. (1994): Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother., 38, 2014-2023.
23. Tung J.U., Johnson J.L., Liacouras C.A. (1996): Portal mesenteric pylephlebitis with hepatic abscesses in a patient with Crohn's disease treated successfully with anticoagulation and antibiotics. J. Pediatr. Gastroenterol. Nutr., 23, 474-478.
24. De Marie-S., Hagenouw-Taal J., Schultze Kool L.J., Meerdink G., Huysmans H.A. et al. (1989): Suppurative thrombophlebitis of superior vena cava. Scand. J. Infect. Dis., 21, 107-111.
25. Committee on the Care and Use of Laboratory animals. (1985): Guides for the Care and Use of laboratory Animals. Institute of Laboratory Animals and Resources. National Research Council, p.83, Washington, DC.
26. Erlendsdottir H., Knudsen J.D., Odenholt I., Cars O., Espersen F., Frimodt-Møller N., Fuursted K., Kristinsson K.G., Gudmundsson S.. (2001): Penicillin pharmacodynamics in four experimental pneumococcal infection models. Antimicrob. Agents Chemother., 45, 1078-1085.
27. Speight T.M., Holford N.H.G. (1997): Avery's Drug Treatment. 4th Edition, Adis International Barcelona, p.1647.
28. Bennet V.J., Brodie I.J., Benner I., E., Kirby N.W. (1966): Simplified accurate method to antibiotic assay of clinical specimens. Appl. Microbiol., 14, 170-177.
29. Tesseromatis C., Fichtl B., Kurz H. (1987): Binding of drugs to liver tissue of rabbits in vitro. Eur. J. Drug Metabol. Pharmacokinet. 12, 161-167.
30. Viani A., Rizzo G., Carrai M., Pacifici G.M. (1992): The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br. J. Clin. Pharmacol., 33, 299-304.
31. Vorum H., Jorgensen H.R., Brodersen R. (1993): Variation in the binding affinity of warfarin and phenprocoumon to human serum albumin in relation to surgery. Eur. J. Clin. Pharmacol., 44, 157-162.
32. Tigka E., Daskala I., Rallis G., Anagnostopoulou S., Tesseromatis C. (2005): Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats. Eur. J. Drug Metabol. Pharmacokinet., 30, 235-241.
33. Tsivou E., Melakopoulos I., Kotsiou A., Anagnostopoulou S., Tesseromatis C. (2005): Alterations in cefalosporin levels in the serum and mandible of hyperlipaedemic rats after co-administration of ibuprofen. Eur. J. Drug Metabol. Pharmacokinet., 30, 171-174.
34. Trichilis A., Saranteas T., Potamianou A., Mourouzis C., Tesseromatis C. (2003): Quinolone levels in serum and maxillofacial tissues under ibuprofen co-administration following surgical trauma. J. Musculoskelet. Neuronal Interact., 3, 170-175.
35. Tesseromatis C., Kotsiou A., Mourouzis C., Saranteas T., Potamianou A., Vairactaris E. (2004): Light- induced changes in quinolone levels in rat serum and tissues. Eur. J. Drug Metabol. Pharmacokinet., 29, 231-233.
36. Saranteas T., Mourouzis C., Dannis C., Alexopoulos C., Lolis E., Tesseromatis C. (2004): Effect of various stress models on lidocaine pharmacokinetic properties in the mandible after masseter injection. J. Oral Maxillofac. Surg., 62, 858-862.
37. Tesserommatis C., Saranteas T., Chatzijanni E., Anagnostopoulou S., Cotsiou A., Chatzi C. (2003): Modifications of clonidine binding to rabbit liver protein under the influence of non-steroid-anti-inflammatory drugs in vitro. Eur. J. Drug Metabol. Pharmacokinet., 28, 245-247.
38. Tesseromatis C., Trichilis A., Tsivos E., Messari J., Triantaphyllidis H., Varonos D.D. (2001): Does stress influence ampicillin concentration in serum and tissues? Eur. J. Drug Metabol. Pharmacokinet., 26, 167-71.
39. Cabana B.E., von Harken D.R., Hottendorf G.H. (1976): Comparative pharmacokinetics and metabolism of cefapirine in laboratory animals and humans. Antimicrob. Agents Chemother., 10, 307-317.
40. Kawamoto K., Touchi A., Sugeno K., Matsubara T. (1988): In vitro effect of beta-lactam antibiotics and N-methyltetrazolethiol on microsomal vitamin K epoxide reductase in rats. Jpn J. Pharmacol., 47, 169-178.
41. Matsubara T., Touchi A., Harauchi T., Takano K., Yoshizaki T. (1989): Depression of liver microsomal vitamin K epoxide reductase activity associated with antibiotic-induced coagulopathy. Biochem. Pharmacol., 38:2693-2701.
42. Creedon K.A., Suttie J.W. (1986): Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase. Thromb. Res. 44, 147-153.
43. Kornguth M.L., Monson R.A., Kumin C.M. (1974): The binding of antibiotics to soluble protein from the rat liver. J. Infect. Dis., 129, 552-558.
44. Ravnan S.L., Locke C. (2001): Levofloxacin and warfarin interaction. Pharmacotherapy, 21, 884-885.
45. Ellis R.J., Mayo M.S., Bodensteiner D.M. (2000): Ciprofloxacin-warfarin coagulopathy: a case series. Am. J. Hematol., 63, 28-31.
46. Israel D.S., Stotka J., Rock W., Sintek C.D., Kamada A.K., Klein C., Swaim W.R., Pluhar R.E., Toscano J.P., Lettieri J.T., Heller A.H., Polk R.E. (1996): Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. Clin. Infect. Dis., 22, 251-256.
47. Jolson H.M., Tanner L.A., Green L., Grasela T.H.,Jr. (1992): Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch. Intern. Med., 151, 1003-1004. Comment in (1992): Arch. Intern. Med., 152, 1533-1534.
48. Sioud M., Possot O., Elie C., Sibold L., Forterre P. (1988): Coumarin and quinolone action in archaebacteria: evidence for the presence of a DNA gyrase-like enzyme. J. Bacteriol., 170, 946-953.
49. Marchbanks C.R. (1993): Drug-drug interactions with fluoroquinolones. Pharmacotherapy., 13(2 Pt 2), 23S-28S.
50. Davey P.G. (1988): Overview of drug interactions with the quinolones. J. Antimicrob. Chemother., 22 Suppl C, 97-107.